Trial · NCT05386459
Study of the Use of the Drug Ingaron in Patients With COVID-19
NCT05386459, Completed, SPP Pharmaclon Ltd.
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Study of the Use of the Drug Ingaron in Patients With COVID-19. Trials, record NCT05386459. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT05386459
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Study of the Use of the Drug Ingaron in Patients With COVID-19
- NCT number
- NCT05386459
- Status
- Completed
- Enrollment
- 36 participants, actual
- Lead sponsor
- SPP Pharmaclon Ltd.
- Conditions
- COVID-19 Respiratory Infection, Viral Pneumonia
- Interventions
- Interferon Gamma
- First posted
- 2022-05-23
- Last updated
- 2022-05-27
Source ClinicalTrials.gov
Registered outcomes14
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Comparative analysis between treatment groups on the WHO Clinical Improvement Scale | Day 14 | The assessment was carried out according to the WHO Clinical Improvement Scale from 0 points - not infected, no manifestations or virological signs of infection, up to 8 points - died, death |
| Secondary | Difference between laboratory LDH values | Day 14 | Difference between laboratory LDH values compared to baseline |
| Secondary | Difference between laboratory CRP values | Day 14 | Difference between laboratory CRP values compared to baseline |
| Secondary | Difference between laboratory ferritin values | Day 14 | Difference between laboratory ferritin values compared to baseline |
| Secondary | Changes in laboratory parameter D-dimer | Day 14 | Changes in laboratory parameter D-dimer compared with baseline |
| Secondary | Comparative analysis of survival between treatment groups | Day 14 | Comparative assessment of CFR mortality rates |
| Secondary | Comparative analysis of survival between treatment groups | Day 14 | Comparative assessment of IFR mortality rates |
| Secondary | Change from baseline patient ratings of subjective outcomes based on various measures | Day 14 | Change from Baseline Patients in Subjective Outcomes Based on: Pulse Oxygen Saturation |
| Secondary | Change from baseline patient ratings of subjective outcomes based on various measures | Day 14 | Change from baseline patient assessments of subjective outcomes based on the indicator: body temperature |
| Secondary | Change from baseline patient ratings of subjective outcomes based on various measures | Day 14 | Change from Baseline Patients in Subjective Outcomes Based on Indicator: Blood Pressure |
1 to 10 of 14Source ClinicalTrials.gov
See all 14 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 33683065 | RESULT |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT05386459
GET https://conductscience.org/api/trials/v1/NCT05386459/registered